

Supplementary Table S1. Types of radiographic progression.

Type of radiographic progression		N
Progression of pre-existing lesions	Stenosis (1)	10
	Wall thickening (2)	3
	Aneurysmal change (3)	2
New lesions	Stenosis (4)	1
	Wall thickening (5)	2
	Aneurysmal change (6)	1
Increased diameter of the aorta (7)		1
Progression of multiple lesions	1 + 2	1
	1 + 3	1
	3 + 7	1
	4 + 5	1
Total		24

Supplementary Table S2. Comparison of clinical characteristics according to the type of radiographic progression.

	Type of radiographic progression		p-value	
	Progression of pre-existing lesions (n = 15)	New lesions Increased diameter of the aorta Progression of multiple lesions (n = 9)		
HTN (%)	9 (60.0)	3 (33.3)	0.399	
DM (%)	1 (6.7)	0 (0.0)	>0.999	
Dyslipidemia (%)	5 (33.3)	2 (22.2)	0.908	
CKD (%)	1 (6.7)	0 (0.0)	>0.999	
Height (cm)	160.42 (7.88)	162.69 (7.66)	0.514	
Body weight (kg)	56.44 (7.95)	56.79 (7.63)	0.920	
AUC of CRP (mg/dL)	0.69 (0.78)	1.85 (1.82)	0.040	
AUC of ESR (mm/h)	27.16 (17.16)	49.99 (32.72)	0.034	
Sex (female, %)	14 (93.3)	8 (88.9)	>0.999	
Age at the initial CTA (year)	33.55 (13.17)	28.92 (11.65)	0.395	
Disease duration (year)	3.61 (5.03)	1.71 (1.72)	0.289	
Type of vascular involvement (%)			0.455	
I	0 (0.0)	0 (0.0)		
IIa	2 (13.3)	4 (44.4)		
IIb	2 (13.3)	1 (11.1)		
III	1 (6.7)	0 (0.0)		
IV	1 (6.7)	0 (0.0)		
V	9 (60.0)	4 (44.4)		
Immunosuppressant use (%)	5 (33.3)	2 (22.2)	0.908	
Steroid use (%)	7 (46.7)	6 (66.7)	0.597	
CTA interval (year)	Mean (SD)	3.23 (0.85)	3.54 (0.87)	0.396
	Median (Q1-3)	2.94 (2.62–3.91)	3.05 (2.77–4.33)	0.371

Values are expressed as n (%) or mean (SD), unless specified otherwise.

CTA: computed tomography angiography; HTN: hypertension; DM: diabetes mellitus; CKD: chronic kidney disease; AUC: area under the curve; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; SD: standard deviation.

Supplementary Table S3. Clinical characteristics of patients with high inflammatory marker levels (AUC of CRP levels ≥ 0.5 mg/dL) and the comparison of characteristics according to radiographic progression.

	Overall (n=46)	Radiographic progression		p-value
		Stable (n=32, 69.6%)	Progression (n=14, 30.4%)	
Sex (female, %)	39 (84.8)	26 (91.2)	13 (92.9)	0.574
Age at the initial CTA (year)	34.01 (12.52)	37.03 (12.43)	27.10 (10.00)	0.012
Disease duration (year)	3.58 (4.81)	3.82 (5.14)	3.03 (4.07)	0.613
Height (cm)	160.81 (7.85)	161.17 (7.91)	159.92 (7.94)	0.633
Body weight (kg)	56.58 (9.30)	57.25 (10.19)	54.91 (6.67)	0.449
HTN (%)	21 (45.7)	15 (46.9)	6 (42.9)	>0.999
DM (%)	3 (6.5)	2 (6.2)	1 (7.1)	>0.999
Dyslipidemia (%)	12 (26.1)	10 (31.2)	2 (14.3)	0.400
CKD (%)	1 (2.3)	1 (3.2)	0 (0.0)	>0.999
AUC of CRP (mg/dL)	1.51 (1.06)	1.38 (0.82)	1.80 (1.45)	0.219
AUC of ESR (mm/h)	43.34 (22.26)	40.70 (19.83)	49.01 (26.67)	0.253
Type of vascular involvement (%)				0.707
I	1 (2.2)	1 (3.1)	0 (0.0)	
IIa	9 (19.6)	5 (15.6)	4 (28.6)	
IIb	7 (15.2)	5 (15.6)	2 (14.3)	
III	0 (0.0)	0 (0.0)	0 (0.0)	
IV	0 (0.0)	0 (0.0)	0 (0.0)	
V	29 (63.0)	21 (65.6)	8 (57.1)	
Azathioprine (%)	3 (6.5)	2 (6.2)	1 (7.1)	>0.999
Methotrexate (%)	13 (28.3)	8 (25.0)	5 (35.7)	0.699
Tacrolimus (%)	1 (2.2)	1 (3.1)	0 (0.0)	>0.999
Leflunomide (%)	1 (2.2)	1 (3.1)	0 (0.0)	>0.999
Infliximab (%)	1 (2.2)	1 (3.1)	0 (0.0)	>0.999
Cyclophosphamide (%)	1 (2.2)	1 (3.1)	0 (0.0)	>0.999
Immunosuppressant use (%)	15 (32.6)	10 (31.2)	5 (35.7)	>0.999
Steroid use (%)	33 (71.7)	23 (71.9)	10 (71.4)	>0.999
CTA interval (year) Mean (SD)	3.37 (0.91)	3.48 (0.91)	3.11 (0.89)	0.213
Median (Q1-3)	3.27 (2.67-4.20)	3.63 (2.95-4.22)	2.77 (2.60-3.86)	0.170

Values are expressed as n (%) or mean (SD), unless specified otherwise.

CTA: computed tomography angiography; HTN: hypertension; DM: diabetes mellitus; CKD: chronic kidney disease; AUC: area under the curve; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; SD: standard deviation.

Supplementary Table S4. Characteristics of patients with low inflammatory marker levels (AUC of CRP levels < 0.5 mg/dL) and the comparison of characteristics according to radiographic progression.

	Overall (n=107)	Radiographic progression		<i>p</i> -value	
		Stable (n=97, 90.7%)	Progression (n=10, 9.3%)		
HTN (%)	76 (71.0)	70 (72.2)	6 (60.0)	0.659	
DM (%)	3 (2.8)	3 (3.1)	0 (0.0)	>0.999	
Dyslipidemia (%)	57 (53.3)	52 (53.6)	5 (50.0)	>0.999	
CKD (%)	4 (3.8)	3 (3.2)	1 (10.0)	0.842	
Height (cm)	159.85 (6.79)	159.54 (6.68)	162.89 (7.47)	0.138	
Body weight (kg)	57.80 (9.49)	57.71 (9.60)	58.71 (8.67)	0.752	
AUC of CRP (mg/dL)	0.15 (0.11)	0.14 (0.11)	0.19 (0.13)	0.222	
AUC of ESR (mm/h)	21.90 (14.19)	22.41 (14.67)	17.12 (6.99)	0.265	
Sex (female, %)	95 (88.8)	86 (88.7)	9 (90.0)	>0.999	
Age at the initial CTA (year)	45.20 (11.71)	45.90 (11.39)	38.41 (13.28)	0.054	
Disease duration (year)	4.23 (6.82)	4.38 (7.02)	2.72 (4.49)	0.464	
Type of vascular involvement (%)				0.363	
I	8 (7.5)	8 (8.2)	0 (0.0)		
IIa	11 (10.3)	9 (9.3)	2 (20.0)		
IIb	17 (15.9)	16 (16.5)	1 (10.0)		
III	4 (3.7)	3 (3.1)	1 (10.0)		
IV	3 (2.8)	2 (2.1)	1 (10.0)		
V	64 (59.8)	59 (60.8)	5 (50.0)		
Azathioprine (%)	2 (1.9)	2 (2.1)	0 (0.0)	> 0.999	
Methotrexate (%)	4 (3.7)	2 (2.1)	2 (20.0)	0.049	
Tacrolimus (%)	0 (0.0)	0 (0.0)	0 (0.0)	NA	
Leflunomide (%)	1 (0.9)	0 (0.0)	1 (10.0)	0.161	
Infliximab (%)	0 (0.0)	0 (0.0)	0 (0.0)	NA	
Immunosuppressant use (%)	6 (5.6)	4 (4.1)	2 (20.0)	0.175	
Steroid use (%)	20 (18.7)	17 (17.5)	3 (30.0)	0.591	
CTA interval (year)	Mean (SD)	3.59 (0.88)	3.59 (0.90)	3.67 (0.72)	0.776
	Median (Q1-3)	3.72 (2.96–4.33)	3.77 (2.98–4.37)	3.64 (2.97–4.23)	0.970

Values are expressed as n (%) or mean (SD), unless specified otherwise.

CTA: computed tomography angiography; HTN: hypertension; DM: diabetes mellitus; CKD: chronic kidney disease; AUC: area under the curve; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; SD: standard deviation.